212 related articles for article (PubMed ID: 30125330)
1. Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies.
Otsuka Y; Schmitt K; Quinlan BD; Gardner MR; Alfant B; Reich A; Farzan M; Choe H
PLoS Pathog; 2018 Aug; 14(8):e1007238. PubMed ID: 30125330
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.
Lynch RM; Wong P; Tran L; O'Dell S; Nason MC; Li Y; Wu X; Mascola JR
J Virol; 2015 Apr; 89(8):4201-13. PubMed ID: 25631091
[TBL] [Abstract][Full Text] [Related]
3. An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes.
Dingens AS; Arenz D; Weight H; Overbaugh J; Bloom JD
Immunity; 2019 Feb; 50(2):520-532.e3. PubMed ID: 30709739
[TBL] [Abstract][Full Text] [Related]
4. Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies.
Hwang JK; Wang C; Du Z; Meyers RM; Kepler TB; Neuberg D; Kwong PD; Mascola JR; Joyce MG; Bonsignori M; Haynes BF; Yeap LS; Alt FW
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):8614-8619. PubMed ID: 28747530
[TBL] [Abstract][Full Text] [Related]
5. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.
Anthony C; York T; Bekker V; Matten D; Selhorst P; Ferreria RC; Garrett NJ; Karim SSA; Morris L; Wood NT; Moore PL; Williamson C
J Virol; 2017 Sep; 91(18):. PubMed ID: 28679760
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody.
Dingens AS; Haddox HK; Overbaugh J; Bloom JD
Cell Host Microbe; 2017 Jun; 21(6):777-787.e4. PubMed ID: 28579254
[TBL] [Abstract][Full Text] [Related]
8. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype.
Mabuka J; Goo L; Omenda MM; Nduati R; Overbaugh J
AIDS; 2013 Jun; 27(10):1535-44. PubMed ID: 23856624
[TBL] [Abstract][Full Text] [Related]
10. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.
Rosenberg Y; Sack M; Montefiori D; Labranche C; Lewis M; Urban L; Mao L; Fischer R; Jiang X
PLoS One; 2015; 10(3):e0120451. PubMed ID: 25807114
[TBL] [Abstract][Full Text] [Related]
12. eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody.
Fellinger CH; Gardner MR; Weber JA; Alfant B; Zhou AS; Farzan M
J Virol; 2019 Jul; 93(14):. PubMed ID: 31068428
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies.
Wang H; Yuan T; Li T; Li Y; Qian F; Zhu C; Liang S; Hoffmann D; Dittmer U; Sun B; Yang R
Arch Virol; 2018 Dec; 163(12):3303-3315. PubMed ID: 30196320
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound.
Cale EM; Bai H; Bose M; Messina MA; Colby DJ; Sanders-Buell E; Dearlove B; Li Y; Engeman E; Silas D; O'Sullivan AM; Mann B; Pinyakorn S; Intasan J; Benjapornpong K; Sacdalan C; Kroon E; Phanuphak N; Gramzinski R; Vasan S; Robb ML; Michael NL; Lynch RM; Bailer RT; Pagliuzza A; Chomont N; Pegu A; Doria-Rose NA; Trautmann L; Crowell TA; Mascola JR; Ananworanich J; Tovanabutra S; Rolland M;
J Clin Invest; 2020 Jun; 130(6):3299-3304. PubMed ID: 32182219
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.
Reh L; Magnus C; Kadelka C; Kühnert D; Uhr T; Weber J; Morris L; Moore PL; Trkola A
PLoS Pathog; 2018 Jan; 14(1):e1006825. PubMed ID: 29370298
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.
Rai MA; Blazkova J; Justement JS; Shi V; Kennedy BD; Manning MR; McLaughlin M; Sneller MC; Pau AK; Moir S; Chun TW
EBioMedicine; 2024 Jun; 104():105151. PubMed ID: 38728839
[TBL] [Abstract][Full Text] [Related]
17. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.
Chen X; Zhou T; Schmidt SD; Duan H; Cheng C; Chuang GY; Gu Y; Louder MK; Lin BC; Shen CH; Sheng Z; Zheng MX; Doria-Rose NA; Joyce MG; Shapiro L; Tian M; Alt FW; Kwong PD; Mascola JR
Immunity; 2021 Feb; 54(2):324-339.e8. PubMed ID: 33453152
[TBL] [Abstract][Full Text] [Related]
18. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies.
Zhou T; Zhu J; Wu X; Moquin S; Zhang B; Acharya P; Georgiev IS; Altae-Tran HR; Chuang GY; Joyce MG; Kwon YD; Longo NS; Louder MK; Luongo T; McKee K; Schramm CA; Skinner J; Yang Y; Yang Z; Zhang Z; Zheng A; Bonsignori M; Haynes BF; Scheid JF; Nussenzweig MC; Simek M; Burton DR; Koff WC; ; Mullikin JC; Connors M; Shapiro L; Nabel GJ; Mascola JR; Kwong PD
Immunity; 2013 Aug; 39(2):245-58. PubMed ID: 23911655
[TBL] [Abstract][Full Text] [Related]
19. A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention.
Kwon YD; Asokan M; Gorman J; Zhang B; Liu Q; Louder MK; Lin BC; McKee K; Pegu A; Verardi R; Yang ES; Program VP; Carlton K; Doria-Rose NA; Lusso P; Mascola JR; Kwong PD
MAbs; 2021; 13(1):1946918. PubMed ID: 34328065
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
